DSB 2004 Program

Session 1: Personalised medicine and nanotechnology
Edison Liu, Genome Institute, Singapore: Gene profiling in breast cancer
Matt Trau, The University of Queensland: Drug & Gene Nano-Balls: Applications of Nanotechnology in Genomics, Proteomics, Drug Discovery and Diagnostics
Rob Sutherland, Garvan Institute of Medical Research: Identification of new prognostic markers and therapeutic targets for prostate cancer through genome wide transcript profiling

Session 2: Genomics and functional genomics
David Martin, Victor Chang Cardiac Research Institute, Sydney: Germline epimutations in human disease
Peter Little, UNSW: Genetic variation and the control of transcription
Dick Cotton, St Vincent's Hospital Melbourne: The problem of collecting all mutations causing inherited disease
Gene Tanimoto, Affymetrix/Millennium Science: The power of the Probe Set: What’s in store for your next Affymetrix Microarray experiment?

Session 3: Bioinformatics
Marc Wilkins, Proteome Systems: Bioinformatics for proteomics: algorithms, integration and visualisation
Mark Ragan, IMB, Queensland: High-throughput bioinformatics: automating the search for lateral gene transfer

Session 4: Proteomics
Julia Wulfkuhle, Clinical Proteomics Program, NIH, Bethesda, Maryland: Protein microarrays: Molecular profiling technologies for diagnosis and monitoring of cancer
Tony Weiss, Sydney University: Proteomics of linked tropoelastin multimers
Stuart Cordwell and Melanie White, APAF
Duncan Veal, FLUOROtechnics, Sydney: Fluorescent Tools in Proteomics

Session 5: From Research to Retail
Stephen Livesey, NSCC, Melbourne: From concept to profitability- One perspective
Greg Collier, Deakin University: AGT Biosciences from Genomics to Therapeutics

Session 6: Natural products and biodiversity
Tony Buss, Merlion Pharma, Singapore: A New Model for Utilising Chemical Diversity from Natural Products
Paul Alewood, University of Queensland: Venoms to drugs
Rohan Davis, Griffith University, QLD: Bioactive Secondary Metabolites from Endophytic Fungi

Session 7: Cancer genomics and proteomics
Jane Armes, University of Melbourne: Genotype-Phenotype correlations in breast cancer
Susan Clark, Sydney Cancer Institute: DNA methylation and gene silencing in cancer
Mark Waltham, St. Vincent's Institute of Medical Research, Melbourne : Gene expression profiling cancer models of epithelial-to-mesenchymal transition
Rob Baxter, Kolling Institute, Sydney : SELDI-TOF in cell biology and diagnostics

Session 8: Protecting and commercialising innovation
Gábor Lamm, EMBLEM, Heidelberg: Turning Ideas into Products: The Innovation Process at EMBL
Richard Jefferson, CAMBIA: The BIOS initiative - open source biology
Vivien Santer, Griffith Hack: Biotechnology Patents- Changes on the Horizon?

Session 9: Brain development and diseases
Peter Schofield, Garvan Institute of Medical Research: Genetic polymorphism (Val66Met) in brain derived growth factor gene associated with deficits in episodic and working memory in humans
Brian Dean, Mental Health Research Institute of Victoria: Combining genomics and proteomics to understand the pathologies of psychiatric illnesses.
Marko Premzl, RSBS, ANU: The prion protein gene: detecting regulatory signals using tammar wallaby sequence

Conference Committee

May 5-7, 2004, Dockside, Cockle Bay Wharf, Sydney, Australia

Convenor Professor Keith Stanley, Centre for Immunology, St Vincents Hospital, Darlinghurst NSW Co-Convenor Professor Erik (Rik) Thompson, University of Melbourne, St Vincents Medical Research Institute Committee Professor Mark Baker Professor Simon Easteal Professor Peter Schofield Mr Iain Scott Professor Matt Trau Professor Deon Venter Dr. Bryce Vissel

Program Committee Professor Paul Alewood Dr. Susan Clark Professor Brian Dean Professor Peter Little Dr. Stephen Livesey Professor Mark Ragan Professor Robert Sutherland Dr. Mark Waltham Professor Tony Weiss Dr. Marc Wilkins